{"nctId":"NCT02096705","briefTitle":"Phase III Insulin Add-On Asia Regional Program - ST","startDateStruct":{"date":"2014-03-31","type":"ACTUAL"},"conditions":["Diabetes"],"count":477,"armGroups":[{"label":"Group 1: Dapagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"Group 2: Dapagliflozin Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Dapagliflozin Placebo"]}],"interventions":[{"name":"Dapagliflozin","otherNames":["BMS-512148"]},{"name":"Dapagliflozin Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c ≥ 7.5% and ≤ 11.0% obtained at screening visit\n* Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at least 8 weeks prior to enrollment\n\nInclusion criteria for randomization:\n\nHbA1c ≥ 7.5 and ≤ 10.5% at Day -14\n\nExclusion Criteria:\n\n* Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of Enrollment\n* History of diabetic ketoacidosis of hyperosmolar nonketotic coma\n* Clinically diagnosed Type 1 diabetes mellitus\n* Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV\n* Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg\n* History of unstable or rapidly progressing renal disease\n* History of severe hepatobiliary disease\n* Mallingancy within 5 years of the screening/enrollment visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c From Baseline to Week 24","description":"The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.0707"},{"groupId":"OG001","value":"-0.87","spread":"0.0666"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24","description":"The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"3.3803"},{"groupId":"OG001","value":"-30.62","spread":"3.1314"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Body Weight From Baseline to Week 24","description":"Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.2224"},{"groupId":"OG001","value":"-1.00","spread":"0.2103"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24","description":"The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"0.3723"},{"groupId":"OG001","value":"-0.70","spread":"0.3592"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":139},"commonTop":["HYPERLIPIDAEMIA","HYPERURICAEMIA","DYSLIPIDAEMIA","UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS"]}}}